AB Science SA (Euronext - FR0010557264 - AB) today announced that the Japanese Patent Office has formally granted a patent for methods of treating progressive multiple sclerosis (MS) with its lead ...

AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS ...

The Pennsylvania affiliate of the Working Families Party said it has launched a new website as part of its campaign to primary Sen. John Fetterman, D-Pa., and "defeat him." "We supported John ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why. Researchers found that inflammation in the brain disrupts the energy supply of ...

Sanofi (SNY) announced on Wednesday that the U.S. FDA issued a complete response letter regarding its marketing application for tolebrutinib, rejecting the drug for patients with multiple sclerosis, ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...

Shares drop after FDA delays decision on tolebrutinib drug Late-stage trial shows drug fails to slow disability progression Analysts fret over Sanofi drug pipeline and investor confidence Dec 15 ...